Author/Editor     Čokolič, Miro
Title     Debelost, metabolni dejavniki tveganja in reductil
Translated title     Obesity, metabolic risk factors and reductil
Type     članek
Source     In: Hojs R, Krajnc I, Pahor A, editors. Zbornik predavanj in praktikum 12. srečanje internistov in zdravnikov splošne medicine Iz prakse za prakso z mednarodno udeležbo; 2001 maj 11-12; Maribor. Maribor: Splošna bolnišnica Maribor,
Publication year     2001
Volume     str. 267-76
Language     slo
Abstract     In developed countries obesity is, the most common chronic disorder and the second most frequent cause of premature morbidity and mortality after smoking. Its health effects are so marked that obesity has now been classified as one of the major health problems. Obesity is a metabolic disorder, characterised by abnormal increase of adipose tissue. It has been epidemiologically shown to be associated with significantly increased risk of: health complications and of co-morbid conditions, such as Type 2 diabetes, dyslipidaemia or hypertension. This group of disorders, also known as the deadly (Kaplan's) quartet extremely increases the risk of developing cardiovascular diseases with a consequent increase in morbidity and mortality. Even a moderate (510%) weight reduction produces a significant effect on cardiovascular risk factors with an improvement in dyslipidaemia and a decrease in blood pressure, uric acid levels, glycaemia and insulinaemia as well as the improvement of glycemic control in Type 2 diabetes. Sibutramine induces weight reduction by enhancing satiety, thus allowing ingestion of smaller meals, while a slight increase in thermogenesis prevents the decline of metabolic rate with hypocaloric diet. Sibutramine induces clinically and statistically significant weight reduction and maintenance of weight loss. With regard to the benefits of sibutramine treatment for metabolic risk factors it seems reasonable to consider such treatment in all obese patients with dyslipidaemia (with or without hypertension) and in all overweight Type 2 diabetic patients.
Descriptors     OBESITY
SEROTONIN UPTAKE INHIBITORS
BODY MASS INDEX
DIET, REDUCING
NOREPINEPHRINE